Brought to you by 
Collegium brings in $86.5mm through public offering
14 Mar 2017
Executive Summary
Collegium Pharmaceutical Inc. (abuse-deterrent pain medications) netted $86.5mm in a public offering of 5.75mm shares (including the overallotment) at $16. The company will use $50mm of the proceeds to fund commercialization activities for its opioid receptor agonist Xtampza ER (oxycodone), which received FDA approval in April 2016 for severe pain. It will also put $8mm toward pipeline R&D, including additional clinical studies for its hydrocodone DETERx abuse-deterrent platform.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Controlled Release
-
Drug Delivery
Deal Status
- Final
Deal Type
-
Financing
- FOPO
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Collegium brings in $86.5mm through public offering
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice